Publications by authors named "Ola M J Alkhozondar"
IMPORTANCE trial: a provisional study-design of a single-center, phase II, double-blinded, placebo-controlled, randomized, 4-week study to compare the efficacy and safety of intranasal esketamine in chronic opioid refractory pain.
Mauricio Fernandes Magdalena Schelotto Philipp Maximilian Doldi Giovanna Milani Abul Andrés Ariza Manzano Ola M J Alkhozondar
F1000Res
June 2021
Article Synopsis
- Cancer is the second leading cause of death worldwide, with a high percentage of advanced patients suffering from significant pain, and limited options for chronic pain management.
- Esketamine, a newer drug with better analgesic effects and fewer side effects than traditional opioids, has been FDA-approved for depression but never tested for chronic cancer pain.
- A proposed phase II trial will test intranasal esketamine in 120 participants with chronic opioid refractory pain to assess its effectiveness and safety, aiming to improve pain management and quality of life.